文献速递乳腺癌支持与姑息治疗

COVID-19疫苗接种后区域淋巴结病:文献综述及乳腺癌诊疗中的患者管理考量

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care.
PubMed 文献 · Eur J Cancer · 2021-10-11

该综述检索多个数据库,纳入15项研究(共2057例患者,其中737例出现淋巴结病),报告COVID-19疫苗接种后区域可触及或影像学检出淋巴结病的发生率范围为14.5%至53%,29%的患者持续超过6周。作者结合Derby和Burton大学医院及Mayo Clinic的病例系列,讨论该现象对乳腺癌诊断与管理的影响,并建议采集准确的疫苗接种史并结合临床判断。

要点

  • COVID-19疫苗接种后区域淋巴结病发生率为14.5%至53%,29%的患者持续超过6周。
  • 乳腺癌患者出现区域淋巴结病时,应采集准确的COVID-19疫苗接种史并结合临床判断。
  • 疫苗相关淋巴结病可能导致不必要的检查、治疗及患者焦虑增加。

核心结论

  • 管理乳腺癌患者的临床医生应知晓COVID-19疫苗接种可能在相当数量的患者中导致区域淋巴结病,进而造成不必要的检查、治疗及患者焦虑增加。
  • 对所有区域淋巴结病为临床和/或影像学发现的患者,应采集准确的COVID-19疫苗接种史,并在个体化管理中结合临床判断。

研究设计与样本

  • 文献综述:检索PubMed、Ovid Medline、Scopus、CINHAL、Springer Nature、ScienceDirect、Academic Search Premier及Directory of Open Access Journals,纳入报告COVID-19疫苗接种后区域可触及或影像学检出淋巴结病的文章。
  • 另汇编来自英国Derby和Burton大学医院及美国明尼苏达州Mayo Clinic的病例系列,用以说明疫苗接种后区域淋巴结病对乳腺诊断和治疗门诊患者诊疗的影响。
  • 文献检索共纳入15项研究,共2057例患者,其中737例有淋巴结病。

主要发现

  • 文献检索纳入的15项研究共2057例患者,其中737例有淋巴结病。
  • 淋巴结病发生率范围为14.5%至53%。
  • 29%的患者淋巴结病持续超过6周。

临床怎么用

  • 对所有区域淋巴结病为临床和/或影像学发现的患者,应采集准确的COVID-19疫苗接种史。
  • 在个体化病例管理中,应将疫苗接种史与临床判断相结合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Over 1 billion doses of COVID-19 vaccines have been already administered across the United States, the United Kingdom and the European Union at the time of writing. Furthermore, 1.82 million booster doses have been administered in the US since 13th August, and similar booster programmes are currently planned or under consideration in the UK and the EU beginning in the autumn of 2021. Early reports showed an association between vaccine administration and the development of ipsilateral axillary and supraclavicular lymphadenopathy, which could interfere with the diagnosis, treatment and follow-up of breast cancer patients. In this paper, we review the available evidence on vaccine-related lymphadenopathy, and we discuss the clinical implications of the same on breast cancer diagnosis and management. METHODS: A literature search was performed - PubMed, Ovid Medline, Scopus, CINHAL, Springer Nature, ScienceDirect, Academic Search Premier and the Directory of Open Access Journals were searched for articles reporting on regional palpable or image-detected lymphadenopathy following COVID-19 vaccination. Separately, we compiled a series of case studies from the University Hospitals of Derby and Burton, United Kingdom and the Mayo Clinic in Minnesota, United States of America, to illustrate the impact that regional lymphadenopathy post-COVID-19 vaccination can have on the diagnosis and management of patients being seen in diagnostic and therapeutic breast clinics. RESULTS: From the literature search, 15 studies met the inclusion criteria (n = 2057 patients, 737 with lymphadenopathy). The incidence of lymphadenopathy ranged between 14.5% and 53% and persisted for >6 weeks in 29% of patients. CONCLUSIONS: Clinicians managing breast cancer patients should be aware that the COVID-19 vaccination may result in regional lymphadenopathy in a significant number of patients, which can result in unnecessary investigations, treatment and increased patient anxiety. An accurate COVID-19 vaccination history should be collected from all patients where regional lymphadenopathy is a clinical and/or an imaging finding and then combined with clinical judgement when managing individual cases.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Garreffa E, Hamad A, O'Sullivan CC, et al. Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care. Eur J Cancer. 2021. PMID: 34731748. doi:10.1016/j.ejca.2021.09.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。